FDA Clearance Tracker · P130029-S004
FLUENCY PLUS ENDOVASCULAR STENT GRAFT
Last checked: Nov 20, 2026Latest source record: Aug 24, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Aug 24, 2016
Approved
Time to decision
194 days
Received Feb 12, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130029-S004
- Device name
- FLUENCY PLUS ENDOVASCULAR STENT GRAFT
- Applicant
- Bard Peripheral Vascular, Inc.
- Applicant location
- Tempe, AZ
- Received
- Feb 12, 2016
- Decided
- Aug 24, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P130029
Device type
- Device type
- System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site located at Sterigenics Belgium Petit-Rechain S.A., Zoning Industriel de petit-Rechain, Avenue Andre Ernst 21, Petit-Rechain, Verviers, 4800, Belgium, for contract sterilization.
Source documents
Other decisions for Bard Peripheral Vascular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250050 · Decided Sep 25, 2026 · 303 days after receipt
Device type: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS (MIR) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.